AMLX News
Archived Headlines
- Updated: Renaissance Capital's 1Q 2022 US IPO Market Review 04/01/22
- Renaissance Capital's January IPO Market Update 02/01/22
- US IPO Weekly Recap: Biotechs ring in the new year in a 4 IPO week 01/07/22
- ALS biotech Amylyx Pharmaceuticals prices upsized IPO at $19 midpoint 01/07/22
- 2022 IPO market kicks off with 3 biotechs set to trade on Friday 01/03/22
See more
Updated: Renaissance Capital's 2022 US IPO Market Review
The IPO Market Flips from Boom to Bust in 2022 After the prior year’s record activity, the 2022 US IPO market ground to a halt as the war in Ukraine, a valuation correction in high-multiple...read more
Nearly 90% of 2022's large IPOs are trading above issue
While market conditions are still keeping the IPO window mostly closed, the year's large issuers are finding support, especially over the past few months. Excluding high-flying outlier HKD, just 15 IPOs have raised $100 million or more in 2022, and 13 (87%)...read more
2022's energy and healthcare IPOs currently average solid returns amid challenging conditions
IPO activity is still muted heading into the final stretch of 2022, weighed down by poor trading from new issuers. Despite challenging current market conditions, the energy and healthcare sectors have delivered solid trading recently, and are the only two...read more
Biotech IPOs struggle to tread water amid challenging market conditions
Despite weak trading in the biotech sector, another drug developer is preparing to take on a challenging IPO market. Norovirus vaccine developer HilleVax (HLVX) plans to raise $175 million this week in the first major biotech IPO of the 2Q. ...read more